Ken Griffin Bristol Myers Squibb CO Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$47.98 - $54.4 $101 Million - $114 Million	2,100,700 Added 73.07%	4,975,700 $270 Million
Q4 2023 Feb 14, 2024	BUY	$48.48 - $57.85 $5.93 Million - $7.08 Million	122,400 Added 4.45%	2,875,000 $148 Million
Q3 2023 Nov 14, 2023	SELL	$57.89 - $64.73 $8.28 Million - $9.26 Million	-143,100 Reduced 4.94%	2,752,600 $160 Million
Q2 2023 Aug 14, 2023	BUY	$63.71 - $70.74 $7.23 Million - $8.03 Million	113,500 Added 4.08%	2,895,700 $185 Million
Q1 2023 May 15, 2023	SELL	$65.71 - $74.53 $17.9 Million - $20.3 Million	-271,900 Reduced 8.9%	2,782,200 $193 Million

Q4 2022 Feb 14, 2023	SELL	$68.48 - $81.09 $50.2 Million - $59.4 Million	-733,000 Reduced 19.36%	3,054,100 $220 Million
Q3 2022 Nov 14, 2022	BUY	$0.13 - $76.84 $66,677 - $39.4 Million	512,900 Added 15.66%	3,787,100 $269 Million

2,554

1.49B

25.9M

20M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $88.3B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.